Inquiry and purchasing guide for larotrectinib medical insurance coverage in 2024

Larotrectinib, an innovative TRK inhibitor known as a "broad-spectrum anticancer drug," is attracting the attention of more and more patients with NTRK gene fusion-positive solid tumors for its unique efficacy. The drug precisely targets the abnormal TRK signaling pathway caused by NTRK gene fusion. It can effectively inhibit the growth and spread of tumors no matter where they originate, bringing hope to patients with various solid tumors such as lung cancer, colorectal cancer, thyroid cancer, and soft tissue sarcoma. In multiple clinical trials, larotrectinib has demonstrated impressive objective response rates (ORR) and durable efficacy.

However, for domestic patients, a practical question is before us: Has larotrectinib been included in the national medical insurance directory? Unfortunately, as of now, although larotrectinib has been approved for marketing in China, it has not yet been included in the medical insurance system. This means that patients need to bear all costs themselves, which undoubtedly increases the financial burden on patients.

Since larotrectinib has been on the market for a relatively short time in China, the supply situation in hospital pharmacies may not be stable. Therefore, it is recommended that patients proactively contact local hospitals or pharmacies to learn about specific purchase channels and availability. In terms of price, the specific price of larotrectinib in China has not yet been fully clarified, but based on the international market, the price of its original drug is generally relatively high, ranging from approximately RMB 10,000 to RMB 20,000 per box. For patients with limited financial conditions, the Lao and Bangladeshi versions of generic drugs may be a more economical choice, with each box selling for about 2,000 to 3,000 yuan.

Although larotrectinib is not yet covered by medical insurance, it still provides new treatment possibilities for specific patient groups. Before use, patients must undergo strict genetic testing and be diagnosed as NTRK gene fusion positive, and use it rationally under the guidance of a doctor to ensure the safety and effectiveness of the treatment. For patients with NTRK gene fusion-positive solid tumors who are looking for effective treatment options, larotrectinib is undoubtedly an option worth looking forward to.

xa0

References:

China National Medical Products Administration:https://www.nmpa.gov.cn/